Search results for " lipid nanoparticle"
Genetic Vaccine Platforms Demonstrate Their Potential
Typically, the RNA or DNA sequence that instructs the human cell to produce the viral antigen(s) intended to trigger an immune response is formulated in a lipid nanoparticle that can enter the human c…
Impact of Media Components on CQAs of Monoclonal Antibodies
The authors review how media components modulate the quality of monoclonal antibody products. By Anurag Rathore, Rajinder Kaur, Dipankar Borgayari Recombinant protein products have…
mRNA: The messenger - LNP formulation
Join us for part 5 of mRNA: the messenger, where we discuss key considerations for the formulation of lipid nanoparticles (LNPs) for mRNA drug delivery, including mixing, encapsulation, polishing and …
Virus-like Particles as Therapeutic Moieties of the Future
Analytical and functional characterization of virus-like particles enables process reproducibility and product consistency. By Ramesh Kumar, Manidipa Banerjee, Anurag S. Rathore Virus-like…
Single-Domain Antibodies for Brain Targeting
Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant production. Smaller recombinant antibody fragments a…
Discussing the Origins of the mRNA Therapeutics Field
Andy Geall, co-founder and chief development officer at Replicate Bioscience, discusses the historical context and buildup of the mRNA therapeutics field. Watch video
How can you harness the potential of nucleic acid therapeutics?
At Cytiva, the new team is here to support you. We can help you throughout the development of your manufacturing workflow for oligonucleotides and the purification of mRNA drug subs…
Can Vaccine Development Be Safely Accelerated?
The company has also developed specific carrier molecules for its mRNA products, including lipid nanoparticles (LNPs), developed in partnership with Acuitas Therapeutics and Arcturus Therapeutics). It…
Biopharma Manufacturers Respond to Ebola Crisis
Tekmira’s antiviral utilizing lipid nanoparticle technology has been authorized for emergency use and is considering options for scale-up to produce some 900 doses by early 2015. And Sarepta Therapeut…